Stages

Surgical Menopause

Creator: Dr Nadira Awal
Published: 2026-01-15

What to expect after having ovaries removed — and why early HRT matters.

By Dr Nadira AwalBMS Specialist4 min readMedically reviewed 9 July 2026

Folded soft hospital gown on cream linen with a small ceramic bowl

Surgical menopause is abrupt and symptoms often severe. UK BMS guidance strongly supports HRT until at least the natural age of menopause, unless contraindicated.

Surgical menopause — usually meaning bilateral oophorectomy (removal of both ovaries), sometimes alongside hysterectomy — is fundamentally different from natural menopause. There is no perimenopausal glide path: hormones fall to postmenopausal levels within 24–48 hours of surgery, and symptoms are typically abrupt, severe and disorienting. For women under 45 in particular, the long-term consequences of untreated surgical menopause are substantial — accelerated bone loss, higher cardiovascular disease, higher rates of cognitive decline and dementia, and reduced life expectancy. Yet with prompt, appropriate HRT (where safe), the vast majority of these excess risks can be prevented. This is one of the areas of menopause medicine where early, confident prescribing changes outcomes the most.

What actually happens at surgery

Bilateral oophorectomy removes the source of oestrogen, progesterone and around half of a woman's testosterone production overnight.
Serum oestradiol falls from premenopausal levels to postmenopausal within 24–48 hours — a far more abrupt drop than the years-long glide of natural menopause.
Symptoms often start within days: intense hot flushes, night sweats, insomnia, low mood, brain fog, joint pain, vaginal dryness, plummeting libido.
Hysterectomy alone (ovaries preserved) usually does not cause immediate menopause, but 20–30% of women experience earlier natural menopause afterwards — the ovarian blood supply is disrupted.
In BRCA1/2 carriers, risk-reducing bilateral salpingo-oophorectomy is typically performed at 35–40 (BRCA1) or 40–45 (BRCA2) — the women who need HRT the longest.

Why early HRT matters — the evidence

Untreated surgical menopause under 45 raises all-cause mortality by around 30% and cardiovascular mortality by up to 80% (Nurses' Health Study, Mayo Clinic Cohort).
Bone mineral density falls by 3–5% per year in the first years after oophorectomy without HRT.
Cognitive decline and dementia risk are significantly higher in women who undergo bilateral oophorectomy before natural menopause without HRT.
The 'timing hypothesis' works in the opposite direction here: HRT started at the time of surgical menopause is protective, not neutral or harmful.
NICE and BMS are unambiguous: women who undergo surgical menopause under 45 should be offered HRT until at least the natural age of menopause (~51), and often longer.

Woman recovering after surgery with a supportive clinician — Surgical menopause is sudden and severe — early, adequate HRT protects bone, heart and brain for decades to come.

Getting the regimen right

Oestrogen: transdermal is usually first-line (Evorel, Estradot patches; Oestrogel, Sandrena, Lenzetto). Doses are commonly higher than for women in natural menopause — 100 mcg patches or 4 pumps of Oestrogel are standard, not exceptional.
Younger women (under 40) may need even higher doses to reach physiological premenopausal oestradiol levels; monitoring oestradiol can guide titration.
Progestogen: only needed if a uterus is retained. Micronised progesterone (Utrogestan 100 mg daily continuous, or 200 mg for 12 nights of a cycle) or a Mirena IUS.
Oestrogen-only (after hysterectomy) has the most favourable breast cancer risk profile of any HRT regimen — WHI data actually show a slight reduction with oestrogen alone.
Testosterone: strongly consider — libido, energy, cognition and mood often lag behind full recovery on oestrogen alone. Baseline total testosterone and SHBG, then Androfeme or Testogel at physiological doses (starting typically 5 mg/day equivalent).
Vaginal oestrogen: almost always helpful for GSM, even on adequate systemic HRT — the vulva and urethra often need local treatment.

Special situation: BRCA carriers and cancer risk-reducing surgery

HRT after risk-reducing bilateral salpingo-oophorectomy (RRBSO) does not appear to increase breast cancer risk in BRCA1 carriers (the strongest evidence to date).
In BRCA2 carriers the picture is more nuanced; oestrogen-only HRT is generally acceptable after hysterectomy, and combined HRT is discussed on an individual basis.
HRT until age 50–51 is the standard recommendation — this is treatment, not lifestyle choice.
Discuss with the specialist familial cancer team and a menopause-informed clinician together.

Transdermal HRT patches, gel and testosterone cream — Regimens after surgical menopause are usually transdermal oestrogen, often at higher doses, with testosterone considered early.

The emotional side — often under-supported

The psychological impact of surgical menopause can be profound — sudden loss of fertility, an accelerated encounter with 'ageing', altered body image, and sometimes an acute grief that surprises women.
Women who had surgery for cancer often navigate menopause and cancer recovery simultaneously — twice the load.
Short-term counselling, peer support (Daisy Network for POI, cancer charities for post-cancer women), and open acknowledgement in clinic all matter.
Partners often struggle too — the change in libido, mood and identity can be sudden and unspoken.

Long-term monitoring

Baseline DEXA scan at or shortly after surgery, then every 2–3 years until stable.
Cardiovascular risk assessment — blood pressure, lipids, HbA1c, QRISK3.
Annual HRT review: symptoms, dose, tolerability, testosterone if used (3–6 monthly initially).
Breast screening as per NHS schedule (or earlier if BRCA carrier — under separate specialist follow-up).
Bone-friendly lifestyle: strength training, protein, calcium 1,000–1,200 mg/day, vitamin D 10–20 mcg daily.

Common mistakes we see referred in

'Standard dose' HRT prescribed — often too low for surgical menopause under 45; women feel undertreated for years.
HRT stopped at 50 or 51 automatically — the natural age of menopause is a floor, not a ceiling.
Testosterone never discussed — one of the most common missed opportunities in surgical menopause care.
Vaginal oestrogen not added — women assume systemic HRT covers it; it often does not.
Symptoms attributed to 'stress' or 'age' rather than under-dosing — resolved once the oestrogen dose is right.

Key takeaway

Surgical menopause deserves earlier, higher-dose and longer HRT than many women are initially offered. For women under 45, HRT until at least the natural age of menopause is not optional — it is standard, evidence-based care that changes long-term outcomes.

How Dr Awal approaches this in clinic

Every consultation starts with your full story — symptoms, cycle, medical history, family history and what you've already tried. From there we look at whether hormonal treatment, non-hormonal options, lifestyle changes or a combination will give you the best result, and we tailor the plan to your age, risk factors and preferences.

A detailed 60 minute first appointment — no rushed 10-minute slots.
Evidence-based recommendations aligned with NICE NG23 and BMS guidance.
Body-identical HRT considered first-line where appropriate.
Shared-care letters sent to your NHS GP so treatment can continue affordably.
Follow-up at 3 months to fine-tune your regimen and address side effects.
Ongoing annual reviews so your plan evolves with you.

Common questions we hear about this

Do I need to be at a certain age to be seen?

No. We see women in early perimenopause (often late 30s and 40s), through post-menopause and beyond. Age alone doesn't decide whether treatment is right — symptoms, health history and goals do.

Will my GP continue the prescription?

In most cases yes. After your consultation we send a detailed shared-care letter with the diagnosis, treatment plan and rationale so your NHS GP can prescribe on the NHS. Not every practice accepts shared care — we'll discuss this in your appointment.

What if I've tried HRT before and it didn't suit me?

Very common — often the type, dose or route wasn't right rather than HRT itself. We review what you've tried, why it didn't work, and adjust accordingly. Many women who thought HRT wasn't for them do well on a different preparation.

How long will I need to stay on treatment?

There is no set upper time limit for HRT. Current BMS and NICE guidance supports continuing HRT for as long as the benefits outweigh the risks for you personally. We review this together every year so you stay in control of the decision.

Where do you see patients?

All consultations at Pause and Co Healthcare are conducted securely via video, allowing us to support patients anywhere in the UK. Prescriptions and shared care arrangements are managed in the same way, regardless of your location.

About the author

Dr Nadira Awal is a British Menopause Society Advanced Menopause Specialist with 15+ years' NHS and private experience. She holds the BMS Advanced Certificate in Menopause Care, sits on the BMS Programme Planning Group, and advises the UK Government Menopause Strategy Group. Read her full profile.

Sources & further reading

General information only — not a substitute for personalised medical advice. Always speak to your GP or a menopause specialist about your own situation.

Talk it through